Breast Cancer highlights from ASCO 2025 with Kevin Kalinsky and Komal Jhaveri

Join our experts as they delve into the latest advancements in breast cancer presented at ASCO 2025, as they comment on highly anticipated trials and gives their perspectives on the significance of the findings and updates. In this episode, Kevin Kalinsky, Emory University Hospital, Atlanta, GA, and Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY, receive updates on trials presented at this year’s ASCO, including the ASCENT-04 trial (NCT05382286) of sacituzumab govitecan and pembrolizumab in PD-L1-positive triple-negative breast cancer (TNBC) and the DESTINY-Breast09 trial (NCT04784715) of first-line trastuzumab deruxtecan (T-DXd) and pertuzumab in patients with HER2+ breast cancer.